Amicus shares tumble as Gaucher trial disappoints
This article was originally published in Scrip
Executive Summary
Shares of Amicus Therapeutics took a dive yesterday after Plicera (afegostat tartrate), its therapy for Gaucher disease, was only effective in one out of 18 patients who completed a Phase II trial.